The startup will use the funding to expand its presence across the US and Europe and accelerate product development.
Founded in 2024 by enterprise technology company veterans with work experience in companies such as Google, Wipro, Infosys, LTI, ServiceNow, Graph AI has built an artificial intelligence platform that automates the processes involving pharmacovigilance and patient safety.
"Pharmacovigilance has traditionally scaled against rising case volumes by adding people and processes around legacy systems. We believe intelligence can change that. Graph Safety gives safety experts an intelligent system that takes on operational complexity, while keeping traceability, accountability, and human oversight at the center,” said Graph AI CEO Raghav Parvataraju.
The startup combines AI with deterministic controls, validation layers, and end-to-end audit trails designed for regulated pharmacovigilance environments. The platform has been designed with reference to applicable regulatory requirements and evolving expectations for AI in medicines development and patient safety.
Graph AI claimed that, in live deployments, its platform has reduced case processing turnaround time from more than 3 hours to under 10 minutes, which lowers operating costs by up to 66%.
The company has onboarded pharmaceutical and biotech customers across North America and other markets, and secured design partnerships for the modules ahead.
Richard Matus, Principal at Insight Partners said, "Pharma companies must strive to get patient safety exactly right, and almost none of them want to be in the business of integrating disparate tools to do it. Meanwhile the software and service providers they rely on haven't kept up with what AI can now do to drive accuracy and value for their pharma customers. "